What is the current domestic market price of zotuximab?

Zolbetuximab (zolbetuximab-clzb)-VYLOY is an innovative targeted monoclonal antibody drug targeting CLDN18.2. It is mainly used to treat patients with CLDN18.2-expressing gastric cancer and gastroesophageal junction adenocarcinoma. This drug activates the antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms in the immune system by specifically binding to the CLDN18.2 protein on the tumor cell membrane, thereby effectively killing tumor cells. Clinical studies have shown that zotuximab significantly improves the efficacy of these advanced patients, especially when combined with standard chemotherapy regimens, showing better clinical benefit.

Globally, zotuximab has been approved by multiple national drug regulatory agencies, includingEMA and PMDA, and has gradually become an important emerging treatment option in the treatment of gastric cancer. Its post-marketing clinical application is mainly focused on those patients who are still relapsed or refractory after standard treatment, especially cases with positive CLDN18.2 expression. Such patients usually have poor prognosis and limited traditional treatment effects, so zotuximab brings them new hope.

In the Chinese market, the original drug of zotuximab has been officially launched, marking the entry of domestic gastric cancer treatment into the era of precise targeting. However, because the drug has just been on the market for a short time, its market price has not yet been fully open and transparent, and it is not currently included in the national medical insurance directory. This means that patients need to obtain the latest price information through designated medical institutions or regular pharmacies when making actual purchases. According to the pricing situation in the international market, the common specifications of the European and Japanese versions of zotuximab are 100mg/bottle, and the price is generally more than RMB 7,000. The price will fluctuate due to exchange rates and regional differences.

It is worth noting that, as a new targeted drug, zotuximab has no generic drugs currently on the market in China, and all drugs used are original products. This guarantees the quality and efficacy of drugs to a certain extent, but it also means that drug prices are relatively high and impose a greater financial burden on patients.

Reference materials:https://www.astellas.com/en/news/29401